Effects on aerosol performance of mixing of either budesonide or beclomethasone dipropionate with albuterol and ipratropium bromide

Respiratory Care

Volumn 56, Issue 3, 2011, Pages 319-326

  Melani, Andrea S ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Aerosol therapy; Albuterol; Asthma; Beclomethasone dipropionate; Budesonide; Corticosteroids; Drug administration; Inhalation; Inhalation therapy: COPD; Ipratropium bromide; Nebulizer

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; IPRATROPIUM BROMIDE; SALBUTAMOL SULFATE;

AEROSOL; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG MIXTURE; EQUIPMENT DESIGN; GRAVIMETRY; IN VITRO STUDY; INHALATIONAL DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MONOTHERAPY; NEBULIZATION; PARTICLE SIZE;

ADMINISTRATION, INHALATION; AEROSOLS; ALBUTEROL; BECLOMETHASONE; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG THERAPY, COMBINATION; HUMANS; IPRATROPIUM; MODELS, BIOLOGICAL; NEBULIZERS AND VAPORIZERS;

EID: 79953156049     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.00955     Document Type: Article

References (27)

1. Dolovich MB. Ahrens RC, Hess DR, Anderson P, Dhand D, Rau JL, et al. Device selection and outcomes of aerosol therapy: evidencebased guidelines: American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Chest 2005;127(1): 335-371.
2. Barta SK, Crawford A, Roberts CM. Survey of patients' views of domiciliary nebulizer treatment for chronic lung disease. Respir Med 2002;96(6):375-381.
3. Melani AS, Sestini P, Aiolfi S, Barbato N, Canessa P, DeAngelis G, et al; Associazione Italiana Pneumologi Ospedalieri (AIPO) Educational Group. GENebu Project: home nebulizer use and maintenance in Italy. Eur Respir J 2001;18(5):758-763.
4. Marcus P, Oppenheimer EA, Patel PA, Katz LM, Doyle JJ. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcome. Ann Allergy Asthma Immunol 2006;96(5): 736-743.
5. Newman SP, Chan HK. In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med Pulm Drug Deliv 2008;21(1):77-84.
6. Nikander K, Turpeinen M, Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med 1999;12(2):47-53.
7. Smaldone GC, Cruz-Rivera M, Nikander K. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension. J Aerosol Med 1998;11:113-125.
8. Berg E, Picard RJ. In vitro delivery of budesonide from 30 jet nebulizer/ compressor combinations. Respir Care 2009;54(12):1671-1678.
9. Pujol MS, Menat C, Henon T, Jacquet M, Woronoff Lemsi MC. [Prescriptions of aerosol therapy. A survey of practices at the Besançon University Hospital] Presse Med 2000;29(15):824-828. Article in French.
10. Melani AS, Pirrelli M, Sestini P, DelDonno M, Bonavia M, Canessa P, et al; Associazione Italiana Pneumologi Ospedalieri Educational Group. GENebu Project Equipment and drugs used for home nebulizer therapy in Italy. Monaldi Arch Chest Dis 2002;57(5-6):231-236.
11. McKenzie JE, Cruz-Rivera M. Compatibility of budesonide inhalation suspension for four nebulizing solutions. Ann Pharmacother 2004;38(6):967-972.
12. Kamin W, Schwabe A, Krämer I. Physicochemical compatibility of fluticasone-17-propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions. Int J Chron Obstruct Pulmon Dis 2007; 2(4):599-607.
13. Bonasia PJ, McVicar WK, Williams B, Ong S. Chemical and physical compatibility of levoalbuterol inhalation solution concentrate mixed with budesonide, ipratropium bromide, cromolyn sodium, or acetylcysteine sodium. Respir Care 2008;53(12):1716-1722.
14. Akapo S, Gupta J, Martinez E, McCrea C, Ye L, Roach M. Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions. Ann Pharmacother 2008;42(10): 1416-1424.
15. Nicolini G, Cremonesi G, Melani AS. Inhaled corticosteroid therapy with nebulized beclomethasone dipropionate. Pulm Pharmacol Ther 2010;23(3):145-155.
16. Karnes HT, Shiu G, Shah VP. Validation of bioanalytical methods. Pharm Res 1991;8(4):421-426.
17. Comité Européen Normalisé. Respiratory therapy equipment: part 1: nebulizing systems and their components. prEN 13544-13551.
18. Dennis JH. Standardization issues: in vitro assessment of nebulizer performance. Respir Care 2002;47(12):1445-1448.
19. Kradjan WA, Lakshminarayan S. Efficiency of air compressor driven nebulisers. Chest 1985;87(4):512-516.
20. Tandon R, McPeck M, Smaldone GC. Measuring nebulizer output. Aerosol production vs. gravimetric analysis Chest 1997;111(5):1361-1365.
21. Barry PW, O'Callaghan C. Drug output from nebulizers is dependent on the method of measurement. Eur Respir J 1998;12(2):463-466.
22. Barry PW, O'Callaghan C. An in vitro analysis of the output of budesonide from different nebulisers. J Allergy Clin Immunol 1999; 104(6):1168-1173.
23. O'Callaghan C. Particle size of beclomethasone dipropionate produced by two nebulisers and two spacer devices. Thorax 1990;45(2): 109-111.
24. Vaghi A, Berg E, Liljedahl S, Svensson JO. In vitro comparison of nebulised budesonide (Pulmicort Respules) and beclomethasone dipropionate (Clenil per aerosol). Pulm Pharmacol Ther 2005;18(2): 151-153.
25. O'Callaghan C, White JA, Jackson JM, Barry PW, Kantar A. Nebulisation of corticosteroids suspensions and solutions with a _2-agonist. J Pharm Pharmacol 2008;60(5):601-605.
26. Berlinski A, Waldrep JC. Nebulized drug admixtures: effect on aerosol characteristics and albuterol output. J Aerosol Med 2006;19(4): 484-490.
27. Di Berardino L, Scaglione F. Mixing albuterol and corticosteroid is not additive. Allergy 1999;54(9):1012-1013.